Blood and CSF chemokines in Alzheimer’s disease and mild cognitive impairment: a systematic review and meta-analysis

被引:0
作者
Futao Zhou
Yangyan Sun
Xinhua Xie
Yushi Zhao
机构
[1] Gannan Medical University,School of Basic Medicine
[2] Gannan Medical University,Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education
来源
Alzheimer's Research & Therapy | / 15卷
关键词
Chemokine; Alzheimer’s disease; Mild cognitive impairment; Meta-analysis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 417 条
[1]  
Tolar M(2020)Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval Alzheimers Res Ther 12 95-172
[2]  
Abushakra S(2021)Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol 17 157-381
[3]  
Hey JA(2012)Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature J Neuropathol Exp Neurol 71 362-732
[4]  
Porsteinsson A(2016)Neuroinflammation in Alzheimer's disease: current evidence and future directions Alzheimers Dement 12 719-S161
[5]  
Leng F(2016)Parkinson's and Alzheimer's diseases: focus on mild cognitive impairment Parkinsonism Relat Disord 22 S159-472
[6]  
Edison P(2018)Microglia in Alzheimer's disease J Cell Biol 217 459-5343
[7]  
Nelson PT(2018)PYNOD reduces microglial inflammation and consequent neurotoxicity upon lipopolysaccharides stimulation Exp Ther Med 15 5337-663
[8]  
Alafuzoff I(2018)Molecular biomarkers of Alzheimer’s disease: progress and prospects Dis Model Mech 11 dmm031781-684
[9]  
Bigio EH(2018)Biomarkers for Alzheimer's disease: current status and prospects for the future J Intern Med 284 643-1390
[10]  
Bouras C(2021)Hypohomocysteinemia may increases the risk of dementia and Alzheimer's disease Clin Nutr 40 5630-716